- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04652219
CART Therapy in GUCY2C-positive Digestive Tract Tumors (CART)
Clinical Study on the Safety and Efficacy of CART Cells in the Treatment of Advanced GUCY2C-positive Digestive Tract Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Weijia Fang
- Phone Number: 18567617799
- Email: fengjingpei@sidansai.com
Study Contact Backup
- Name: Jingpei Feng
- Phone Number: 18567617799
- Email: fengjingpei@sidansai.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310006
- First affiliated hospital, Zhejiang University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1. Aged between 18 and 70; 2. Positive expression of immunohistochemical (IHC) assay targets in a laboratory approved by the partner; 3. Pathology confirmed digestive tract tumor; 4. Patients who have failed or relapsed after at least the first and second line standard treatment, and patients who are intolerant to or voluntarily give up the standardized treatment; 5. At least one extracranial measurable lesion according to RECIST1.1 or EORTC or PERCIST; 6. Expected survival ≥90 days; 7. The main organs are functioning normally, i.e. they meet the following criteria:
- ECOG physical condition score is 0~1 or KPS score is >70;
- serum test criteria were as follows: HB≥90g/L (no blood transfusion within 14 days), ANC≥ 1.5 x 10^9/L, PLT≥80 x 10^9/L, Alb ≥ 2.8g/dL, serum lipase and amylase < 1.5×ULN (upper limit of normal value).
- Biochemical examination shall meet the following standards: TBIL≤ 1.5x ULN (upper limit of normal value); ALT and AST≤ 2.5x ULN; ALT and AST≤5xULN in case of liver metastasis; Serum Cr≤1xULN, endogenous creatinine clearance rate >50 ml/min (Cockcroft-Gault formula);
- cardiac ejection fraction >55%; 8. No hemorrhagic disease or coagulation disorder; 9. No allergy to the developer; 10. Women of childbearing age must undergo a pregnancy test (serum or urine) within 7 days prior to enrollment, with negative results, and be willing to use an appropriate method of contraception during and 8 weeks after the last dose of CART (women who have undergone sterilization or have been postmenopausal for at least 2 years may be considered sterile); 11. The subjects voluntarily joined the study, signed the informed consent form, had good compliance and cooperated with the follow-up.
Exclusion Criteria:
- T cell transduction efficiency <5% or T cell amplification < 2 times after culture;
- Participated in other drug clinical trials within 4 weeks before the start of the study;
- Patients with hypertension and unable to obtain good control by single antihypertensive drugs (systolic blood pressure > 140 mmHg, diastolic blood pressure b> 90 mmHg, the specific conditions shall be evaluated by the researchers) have myocardial ischemia or infarction of grade I or above, arrhythmia of grade I or above (including QT interval ≥ 440ms) or cardiac insufficiency;
- A wound or fracture in the chest or other area that has not healed for a long time;
- Has a history of substance abuse and is unable to quit or has a history of mental disorders;
- Patients with past or present objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radioactive pneumonia, drug-related pneumonia, severe pulmonary function impairment, etc.;
- Fungus, bacteria, virus or other infection that cannot be controlled or requires antibiotic treatment. The presence of a simple urinary tract infection and uncomplicated bacterial pharyngitis is permitted after consultation with a medical supervisor;
- For subjects who have used chemotherapy before, according to NCI-CTCAE 4.0, there is grade ≥2 hematological toxicity or grade ≥3 non-hematological toxicity at the time of enrollment;
- A known history of HIV, or a positive nucleic acid test for hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive);
- The presence of any indwered catheter or drainage tube (e.g., bile drainage tube or pleural/peritoneal/pericardial catheter). The use of specialized central venous catheters was permitted (the influence of fistula, percutaneous nephrostomy, and indwsed Foley catheters in colorectal cancer patients was considered by the investigators);
- Brain metastases; A history or medical condition of CNS, such as seizure disorder, cerebral ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving CNS;
13. Significant immunodeficiency; 14. The major therapeutic drugs in this study (including fludalabine, cyclophosphamide, sodium meth, and tozumab and anti-infective drugs used to prevent and treat CRS) have a history of severe hypersensitivity reaction; 15. History of deep vein thrombosis or pulmonary embolism 6 months before enrollment; 16. A history of an autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) that has resulted in injury to the terminal organs or that requires systemic immunosuppressive/disease-modulating drugs in the past 2 years; 17. Any disease that may interfere with the evaluation of the safety or efficacy of the study treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with late malignant digestive tract tumor
Patients with late malignant digestive tract tumor, for example metastatic colorectal cancer, pancreatic cancer, gastric cancer and so on.
because of this is a open, single arm trail, there is no control group.
|
Patients with advanced malignant gastrointestinal tumors were injected with CART cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with CAR-T treatment-related adverse events as assessed by CTCAE v4.03
Time Frame: 24 months
|
The investigator is responsible for ensuring that all adverse events observed by the investigator or reported by the subject during the 3-month period from enrollment (i.e.
initiation of leukocyte separation) to 3 months after targeted car-t infusion are monitored and reported.
After three months, researchers will be required to monitor and report targeted adverse events, including neurological, blood, infection, autoimmune diseases, and secondary malignant tumors, for 24 months or until disease progression, whichever occurs first.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The event of cytokine release syndrome was reported using the grading scale in the protocol.
Time Frame: 24 months
|
We will summarize the classification of cytokine release syndrome (CRS) according to the severity and system organ classification.
|
24 months
|
Efficacy will be assessed according to RECIST1.1 or EORTC or PERCIST criteria.
Time Frame: 24 months
|
Remission will be evaluated by the central investigator at the time indicated in the evaluation plan.
The disease was evaluated according to the response evaluation criteria in solid tumors RECIST version 1.1 or EORTC or percist.
Flow cytometry, molecular or cytogenetic studies used in the trial will be used to assist, but will not be used alone to determine remission.
|
24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Weijia Fang, First Affiliated Hospital,Zhejiang University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICT-GC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Neoplasms of Digestive Organs
-
M.D. Anderson Cancer CenterMerck Sharp & Dohme LLCCompletedMalignant Neoplasms of Female Genital Organs | Malignant Neoplasms of Urinary Tract | Malignant Neoplasms of Digestive Organs | Malignant Neoplasms of Male Genital OrgansUnited States
-
M.D. Anderson Cancer CenterMerck Sharp & Dohme LLC; BioMed Valley Discoveries, IncActive, not recruitingMalignant Neoplasms of Female Genital Organs | Malignant Neoplasm of Breast | Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Malignant Neoplasms of Independent (Primary) Multiple Sites | Malignant Neoplasms of Mesothelial... and other conditionsUnited States
-
M.D. Anderson Cancer CenterMillennium Pharmaceuticals, Inc.WithdrawnMalignant Neoplasms of Female Genital Organs | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Malignant Neoplasms of Digestive Organs | Malignant Neoplasms of Male Genital Organs
-
M.D. Anderson Cancer CenterEisai Inc.WithdrawnAdvanced Cancer | Malignant Neoplasms of Female Genital Organs | Malignant Neoplasm of Breast | Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Malignant Neoplasms of Independent (Primary) Multiple Sites | Malignant Neoplasms... and other conditions
-
M.D. Anderson Cancer CenterAstraZenecaActive, not recruitingMalignant Neoplasms of Female Genital Organs | Malignant Neoplasm of Breast | Malignant Neoplasms of Thyroid and Other Endocrine Glands | Malignant Neoplasms of Digestive Organs | Malignant Neoplasms of Male Genital OrgansUnited States
-
Innovative Cellular Therapeutics Co., Ltd.Anhui Provincial Cancer HospitalNot yet recruiting
-
Zhejiang Cancer HospitalSun Yat-sen University; Shanghai Zhongshan Hospital; Fujian Cancer Hospital; RenJi... and other collaboratorsRecruitingMalignant Tumors of Digestive TractChina
-
Sahlgrenska University Hospital, SwedenThe Swedish Research Council; Sjöbergstiftelsen; VGregionRecruitingGynecologic Cancer | Malignant Neoplasm | Malignant Neoplasm of Large Intestine | Malignant Neoplasm of Colon | Malignant Neoplasm of Prostate | Malignant Neoplasm of Rectum | Malignant Neoplasm of Anus | Malignant Neoplasm of Urinary Bladder | Malignant Neoplasm of Cervix | Malignant Neoplasm of OvarySweden
-
M.D. Anderson Cancer CenterGateway for Cancer Research; James B. and Lois R. Archer Charitable FoundationRecruitingMalignant Neoplasms of Female Genital Organs | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Melanoma and Other Malignant Neoplasms of Skin | Malignant Neoplasm of Bone and Articular Cartilage | Malignant Neoplasms of Independent (Primary) Multiple Sites | Malignant Neoplasm of Male... and other conditionsUnited States
-
Istituto Clinico HumanitasTerminatedSecondary Malignant Neoplasm of LiverItaly
Clinical Trials on gucy2c cart cells
-
Innovative Cellular Therapeutics Co., Ltd.Anhui Provincial Cancer HospitalNot yet recruiting
-
Fujian Medical UniversityUnknown
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Second Affiliated Hospital of Suzhou UniversityUnknown
-
The Affiliated Hospital of the Chinese Academy...Unknown
-
The Affiliated Hospital of the Chinese Academy...UnknownLeukemia, Lymphocytic, AcuteChina
-
Fujian Medical UniversityUnknown
-
University of PennsylvaniaTerminated
-
University of PennsylvaniaUniversity of California, San FranciscoTerminatedPatients With Residual or Reccurent EGFRvIII+ GliomaUnited States
-
su haichuanNot yet recruiting
-
Aeon Therapeutics (Shanghai) Co., Ltd.Renmin Hospital of Wuhan University; Eureka Therapeutics Inc.TerminatedLiver Neoplasms | Hepatocellular Carcinoma | Liver Cancer | Metastatic Liver CancerChina